Lee's Pharmaceutical Holdings Limited 0950

1cBio, a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm"), today announced that the companies have entered into a licensing agreement granting Lee's Pharm exclusive rights to develop and commercialize 1cBio's lead PARP1 inhibitor, OC-3, in China and certain countries in Southeast Asia. Under the terms of the agreement, 1cBio

NEW YORK, July 21, 2026--Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience.

As global markets navigate a week marked by volatility and geopolitical tensions, small-cap stocks continue to capture attention with their potential for growth amid fluctuating economic indicators. In this dynamic environment, identifying undiscovered gems requires a keen eye for companies that demonstrate resilience and adaptability, particularly those poised to benefit from shifts in trade policies or emerging market trends.

As global markets navigate a period of volatility, with major indices like the S&P MidCap 400 and Russell 2000 experiencing slight declines amid geopolitical tensions and economic shifts, investors are increasingly on the lookout for potential opportunities in lesser-known stocks. In this environment, identifying undiscovered gems often involves seeking out companies with strong fundamentals that can withstand market fluctuations and benefit from improving economic indicators such as higher...